生物制药公司Hoth Therapeutics宣布，其研发的GDNF疗法在实验研究中展现出显著效果——能够将体重增长幅度抑制10%至15%。值得注意的是，在治疗周期的最后几周，受试者的体重数据进入平台期，不再呈现明显上升趋势。
生物制药公司Hoth Therapeutics宣布，其研发的GDNF疗法在实验研究中展现出显著效果——能够将体重增长幅度抑制10%至15%。值得注意的是，在治疗周期的最后几周，受试者的体重数据进入平台期，不再呈现明显上升趋势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.